Skip to main content
Jia Li, MD, Oncology, New York, NY, Memorial Sloan Kettering Cancer Center

JiaLiMD

Oncology New York, NY

Assistant Professor, Comprehensive Cancer Center, Yale University School of Medicine

Overview of Dr. Li

Dr. Jia Li is an oncologist in New York, NY and is affiliated with multiple hospitals in the area, including Memorial Sloan Kettering Cancer Center, Veterans Affairs Connecticut Healthcare System, and St. Catherine of Siena Hospital. She received her medical degree from Tianjin Medical University and has been in practice 22 years. She is one of 20 doctors at Veterans Affairs Connecticut Healthcare System and one of 463 doctors at Memorial Sloan Kettering Cancer Center who specialize in Oncology. She has more than 30 publications and over 500 citings.

Education & Training

  • Yale-New Haven Medical Center
    Yale-New Haven Medical CenterFellowship, Hematology and Medical Oncology, 2007 - 2010
  • Montefiore Medical Center/Albert Einstein College of Medicine (Moses and Weiler Campuses)
    Montefiore Medical Center/Albert Einstein College of Medicine (Moses and Weiler Campuses)Residency, Internal Medicine, 2004 - 2007
  • Tianjin Medical University
    Tianjin Medical UniversityClass of 1995

Certifications & Licensure

  • FL State Medical License
    FL State Medical License 2022 - Present
  • NY State Medical License
    NY State Medical License 2010 - 2025
  • NJ State Medical License
    NJ State Medical License 2019 - 2025
  • American Board of Internal Medicine Medical Oncology

Publications & Presentations

PubMed

Journal Articles

  • Macrophage Migration Inhibitory Factor Mediates Metabolic Dysfunction Induced by Atypical Antipsychotic Therapy  
    Jia Li, Lawrence Young, Richard Bucala, The Journal of Clinical Investigation

Press Mentions

  • Phase 2 Study of Parsaclisib (INCB050465), a Highly Selective, Next-Generation PI3Kδ Inhibitor, in Relapsed or Refractory Diffuse Large B-cell Lymphoma (CITADEL-202)
    Phase 2 Study of Parsaclisib (INCB050465), a Highly Selective, Next-Generation PI3Kδ Inhibitor, in Relapsed or Refractory Diffuse Large B-cell Lymphoma (CITADEL-202)November 3rd, 2020
  • Scientists Develop Highly Effective Tumor Detection Strategy for Common Childhood Brain Tumors
    Scientists Develop Highly Effective Tumor Detection Strategy for Common Childhood Brain TumorsOctober 20th, 2020
  • Suny Downstate Medical Center Reviews
    Suny Downstate Medical Center ReviewsAugust 1st, 2021

Hospital Affiliations